Duration of Response With Sonrotoclax Vs Current Therapies for MCL

Data presented at ASH 2025 highlighted the potential of sonrotoclax, an investigational BCL2 inhibitor, in the treatment of relapsed/refractory mantle cell lymphoma (MCL). Michael Wang, MD, emphasized that evaluating a new therapy requires assessing both the depth of response and the durability of benefit. In this study, responses were defined by tumor reduction, with partial remission reflecting more than a 50% reduction in tumor burden and complete remission indicating near-total disease clearance.

Sonrotoclax demonstrated a total overall response rate of 52%, including a complete response rate of 16%. However, Wang stressed that response rates alone are insufficient if the benefit is short-lived. Durability of response emerged as a key strength of sonrotoclax in this analysis.

Among patients who achieved either partial or complete remission, the median time to next treatment was 16 months, suggesting sustained disease control and prolonged clinical benefit. This duration compares favorably with many currently available targeted agents, which often induce responses that last 1 to 2 years at most.

Additional efficacy measures further supported the durability of benefit. The reported median progression-free survival was 6.5 months, exceeding outcomes observed with certain approved therapies in similar relapsed/refractory MCL populations. With a current median follow-up of approximately 14 months, longer observation is needed to fully characterize progression-free survival trends and to determine overall survival outcomes. Notably, median overall survival has not yet been reached.

Wang concluded that sonrotoclax offers a balanced profile of good response rates and clinically meaningful durability, positioning it as a promising therapeutic option for patients with relapsed/refractory MCL.